The CD70 Vorsetuzumab Biosimilar Antibody (HDBS0005) is a cutting-edge tool for investigating the CD70 protein, a key player in immune responses and cancer development. This monoclonal antibody, developed as a biosimilar to Vorsetuzumab, binds specifically to CD70 in human samples, allowing for precise detection and analysis in research settings. CD70, a member of the tumor necrosis factor (TNF) superfamily, is a promising target for immunotherapy due to its role in promoting tumor growth and immune evasion.
By blocking CD70 activity, this antibody has the potential to disrupt cancer cell signaling pathways and enhance anti-tumor immune responses.With its high specificity and reliability, the Anti-CD70 Vorsetuzumab Biosimilar Antibody is a valuable tool for studying CD70 function in cancer biology and exploring its potential as a therapeutic target. Researchers in oncology and immunology will find this antibody essential for elucidating the mechanisms of CD70-mediated immune regulation and tumor progression.
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Storage & Shipping:
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).Lyophilized antibodies are shipped at ambient temperature.
Common Name:
SGN-70, h1F6
Buffer:
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Format:
Powder
Applications
ELISA, Flow Cyt
Antibody Isotype:
IgG1
Guarantee:
12 months from date of dispatch
Background:
Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
